Skip to main content
    J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $210.39
    -6.36 (-2.93%)

    Market Cap: $13.61B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    +0.48%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$3.10
    Range$-4.93 - $6.95
    19 analysts
    EPS Revisions
    1
    0
    7d
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$6.34-51.1%
    60d ago$6.52-52.5%
    30d ago$6.46-52.0%
    7d ago$5.84-46.9%
    Current$3.10
    Revenue Consensus
    $1.2B
    Range$1.2B - $1.2B
    18 analysts
    Period ending Dec 31, 2026
    EPS Consensus$7.72
    Range$-0.58 - $12.22
    19 analysts
    Revenue Consensus
    $1.4B
    Range$1.3B - $1.5B
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$7.72---
    Sep 26EST
    		-$3.10---
    Jun 26
    Reported Aug 3
    		$4.89$5.06-3.36%Miss+159.3%
    Mar 26
    Reported May 5
    		$6.34$4.66+36.05%Beat+277.4%
    Dec 25
    Reported Feb 24
    		$6.64$6.51+2.05%Beat+0.6%
    Sep 25
    Reported Nov 5
    		$6.99$4.80+45.63%Beat+5.7%
    Jun 25
    Reported Aug 5
    		$-8.25$-6.25-32.00%Miss-255.7%
    Mar 25
    Reported May 6
    		$1.68N/A-63.95%Miss-37.3%
    Dec 24
    Reported Feb 25
    		$6.60$5.81+13.58%Beat+31.5%
    Sep 24
    Reported Nov 6
    		$6.61$5.50+20.18%Beat+36.6%
    Jun 24
    Reported Jul 31
    		$5.30$4.78+10.88%Beat+17.5%
    Mar 24
    Reported May 1
    		$2.68$4.18-35.89%Miss-32.2%
    Dec 23
    Reported Feb 28
    		$5.02$5.18-3.09%Miss+7271.4%
    Sep 23
    Reported Nov 8
    		$4.84$4.93-1.83%Miss-6.4%
    Jun 23
    Reported Aug 9
    		$4.51$4.43+1.81%Beat+4.9%
    Mar 23
    Reported May 10
    		$3.95$4.22-6.40%Miss+5.9%
    Dec 22
    Reported Mar 1
    		$-0.07N/A-121.88%Miss-101.7%
    Sep 22
    Reported Nov 9
    		$5.17$4.67+10.71%Beat+23.1%
    Jun 22
    Reported Aug 3
    		$4.30$4.19+2.63%Beat+10.3%
    Mar 22
    Reported May 4
    		$3.73$3.89-4.11%Miss-4.8%
    Dec 21
    Reported Mar 1
    		$4.21$3.64+15.66%Beat+5.2%
    Sep 21
    Reported Nov 9
    		$4.20$3.31+26.89%Beat-2.6%
    Jun 21
    Reported Aug 3
    		$3.90$3.45+13.04%Beat+5.1%
    Mar 21
    Reported May 4
    		$3.92$3.73+5.09%Beat+771.1%
    Dec 20
    Reported Feb 23
    		$4.00$4.20-4.76%Miss-9.5%
    Sep 20
    Reported Nov 2
    		$4.31$4.08+5.64%Beat+5.1%
    Jun 20
    Reported Aug 4
    		$3.71$3.11+19.29%Beat-8.4%
    Mar 20
    Reported May 5
    		$0.45$0.67-32.84%Miss-87.7%
    Dec 19
    Reported Feb 25
    		$4.42$4.12+7.28%Beat+21.4%
    Sep 19
    Reported Nov 5
    		$4.10$3.59+14.21%Beat+14.5%
    Jun 19
    Reported Aug 6
    		$4.05$3.57+13.45%Beat+16.0%
    Mar 19
    Reported May 7
    		$3.67$3.16+16.14%Beat+23.2%
    Dec 18
    Reported Feb 26
    		$3.64$3.02+20.53%Beat+23.4%
    Sep 18
    Reported Nov 6
    		$3.58$3.32+7.83%Beat+11.2%
    Jun 18
    Reported Aug 7
    		$3.49$3.21+8.72%Beat+36.3%
    Mar 18
    Reported May 8
    		$2.98$2.78+7.19%Beat+29.0%
    Dec 17
    Reported Feb 27
    		$2.95$2.98-1.01%Miss+8.9%
    Sep 17
    Reported Nov 7
    		$3.22$2.89+11.42%Beat-
    Jun 17
    Reported Aug 8
    		$2.56$2.75-6.91%Miss-
    Mar 17
    Reported May 9
    		$2.31$2.34-1.28%Miss-
    Dec 16
    Reported Feb 28
    		$2.71$2.65+2.26%Beat-

    Key Metrics

    Valuation
    P/E Ratio8.46EV/EBITDA9.91x
    Price/FCF8.78xFCF Yield11.39%
    Profitability
    Profit Margin20.40%Operating Margin26.90%
    ROE22.10%ROIC9.82%
    Financial Health
    Debt/Equity0.91xInterest CoverageN/A
    Current Ratio1.78xQuick Ratio1.58x
    Trading Statistics
    Beta0.37Avg Volume834.10K
    52-Week High$266.3852-Week Low$128.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$226.68
    SMA 20$232.84
    SMA 50$242.85
    SMA 200$213.86
    EMA 10$224.35
    EMA 20$230.58
    EMA 50$237.39
    EMA 200$214.84

    MACD

    Line: -7.04Signal: -4.87Hist: -2.17

    ADX

    ADX: 32.5+DI: 8.2-DI: 35.6

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down100.0
    PSAR$233.17

    Bollinger Bands

    Upper Band$251.24
    Lower Band$214.44
    %B Position1581%(Upper)
    Band Width-0.11

    RSI (14-Day)

    Oversold
    22.1

    Momentum Oscillators

    Stoch %K11.2
    Stoch %D17.4
    Williams %R-96.5
    ROC (10d)-9.5%
    Momentum-21.96
    CCI (20d)-216.7
    MFI (14d)22.4

    Volatility Measures

    ATR (14d)$7.33(3.5%)
    StdDev (20d)9.20
    Hist Vol22.9%(Moderate)

    Volume Flow

    VWAP$212.20
    OBV42.0M
    AD Line21.4M
    CMF (20d)-0.141

    Volume Metrics

    Avg Vol (20d)859.1K
    Vol Ratio0.9x
    VWMA (20d)$232.30

    Pivot Points

    R3$225.72
    R2$223.86
    R1$220.30
    Pivot Point$218.44
    S1$214.88
    S2$213.02
    S3$209.46

    Advanced Oscillators

    TSI-34.56
    Ultimate Osc39.3
    KST-71.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.21B$1.07B$1.20B$1.13B$1.05B$897.80M$1.09B$1.05B$1.02B$901.98M$1.01B$972.14M
    Cost of Revenue$116.40M$134.10M$153.53M$128.88M$116.30M$104.60M$128.71M$111.61M$109.90M$95.49M$107.24M$102.15M
    Gross Profit$1.09B$934.80M$1.04B$997.23M$929.40M$793.20M$959.46M$943.36M$913.92M$806.50M$904.69M$869.99M
    Operating Expenses$843.70M$598.20M$789.86M$939.72M$1.62B$849.10M$768.69M$683.15M$714.48M$740.29M$782.20M$697.60M
    R&D$284.50M$196.00M$213.91M$240.70M$1.10B$180.70M$240.50M$199.92M$220.73M$232.85M$234.61M$234.40M
    SG&A$389.20M$352.70M$406.21M$530.65M$358.40M$514.00M$369.29M$325.77M$338.52M$351.71M$396.03M$308.31M
    Operating Income$248.20M$336.60M$254.53M$57.51M$-686,400,000$-55,900,000$190.77M$260.21M$199.44M$66.21M$122.50M$172.39M
    Interest Income$-37,100,000$-39,900,000$-45,406,000$-48,576,000$-47,400,000$-53,700,000$-51,256,000$-58,702,000$-62,023,000$-66,116,000$-70,324,000$-71,497,000
    Interest Expense$37.20M$37.40M$46.06M$48.47M$49.20M$53.90M$57.55M$59.40M$61.52M$67.81M$60.97M$72.87M
    Income Before Tax$211.00M$299.20M$208.47M$9.04M$-735,600,000$-109,800,000$133.22M$200.81M$137.93M$-1,602,000$61.53M$99.52M
    Income Tax Expense$18.10M$6.10M$4.96M$-242,424,000$-17,200,000$-17,800,000$-57,912,000$-14,533,000$-30,653,000$11.67M$-33,089,000$-47,176,000
    Net Income$192.80M$293.10M$203.45M$251.41M$-718,500,000$-92,500,000$191.12M$215.06M$168.57M$-14,618,000$94.15M$146.82M
    EBITDA$427.20M$520.50M$433.05M$235.86M$-514,200,000$108.70M$352.89M$424.74M$362.99M$227.90M$291.05M$333.57M
    EBIT$248.10M$339.10M$253.88M$57.61M$-688,200,000$-56,100,000$184.47M$259.51M$199.95M$64.51M$131.85M$171.01M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JAZZ

    Government Contracts

    Gov Obligations (TTM)
    $176384
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    -92.0%
    Active Awards
    18
    New Awards (TTM)
    6
    Avg Remaining Term
    1.9 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0146Department of Veterans AffairsDepartment of Veterans Affairs$397859Feb 1, 2026
    36C26026F0013Department of Veterans AffairsDepartment of Veterans Affairs$231127Oct 1, 2025
    36C26026F0012Department of Veterans AffairsDepartment of Veterans Affairs$133028Oct 1, 2025
    36C24526N0282Department of Veterans AffairsDepartment of Veterans Affairs$14672Jan 31, 2026
    36C24526N0198Department of Veterans AffairsDepartment of Veterans Affairs$14243Dec 23, 2025
    36C26026F0027Department of Veterans AffairsDepartment of Veterans Affairs$0Oct 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    What Jazz Pharmaceuticals Buyers Were Betting On

    Investors in Jazz Pharmaceuticals saw a 21.1% gain this year, driven by bullish bets on new therapies despite patent worries and trial setbacks. The company's FDA approval for Ziihera in gastroesophageal cancer supported...

    Simply Wall Street•10/15/26•Somewhat-Bullish

    Jim Cramer Gives Green Light To This Health Care Stock

    Jim Cramer highlighted several stocks on his "Mad Money Lightning Round," giving a "yes" to Jazz Pharmaceuticals (NASDAQ:JAZZ)...

    Benzinga•10/12/26•Somewhat-Bullish

    Jazz Pharmaceuticals (JAZZ) Faces A Succession Test Following An Undervalued View

    Jazz Pharmaceuticals (JAZZ) is facing a succession challenge as its Executive Vice President and Chief Commercial Officer announced her retirement...

    Simply Wall Street•10/10/26•Neutral

    Jazz Pharmaceuticals (JAZZ) Faces A Succession Test Following An Undervalued View

    Jazz Pharmaceuticals (JAZZ) is facing a succession test as its Executive Vice President and Chief Commercial Officer plans retirement, leading to a search for a successor. Despite recent share price pullbacks...

    Simply Wall Street•10/10/26•Somewhat-Bullish

    Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 10 October

    This article announces the filing of Form 144 for Jazz Pharmaceuticals Public Limited Company, pertaining to October 10. It is a brief...

    Investing.com Australia•10/10/26•Neutral

    JAZZ Valuation and Fair Value

    P/E
    8.5x
    Forward P/E
    10.9x
    EV/EBITDA
    9.9x
    P/FCF
    8.8x
    PEG
    1.0x
    P/B
    2.8x
    See GNG's fair value

    JAZZ Profitability: Margins, ROIC and FCF

    Gross margin
    88.4%
    Operating margin
    26.9%
    Net margin
    20.4%
    ROIC
    9.8%
    ROE
    22.1%
    FCF margin
    32.9%
    FCF yield
    11.4%

    JAZZ Competitors

    CompanyTicker
    Neurocrine Biosciences IncNBIX
    Halozyme Therapeutics IncHALO
    Charles River LaboratoriesCRL
    ICON PLCICLR
    Ascendis Pharma ASASND
    Summit Therapeutics PLCSMMT
    Solventum Corp.SOLV
    Baxter International IncBAX

    Sector: Healthcare

    JAZZ Analyst Ratings

    Consensus
    Buy
    Analysts
    22
    Strong Buy
    7
    Buy
    13
    Hold
    2
    Sell
    0
    Strong Sell
    0

    JAZZ Bull Case vs Bear Case

    Bull case

    • JAZZ converts 32.9% of revenue into free cash flow.
    • JAZZ has a 20.4% net profit margin.
    • JAZZ grew quarterly revenue 15.5% year over year.

    JAZZ Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    2.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $3.10
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 2 down

    Frequently Asked Questions About JAZZ

    Does JAZZ pay dividends?

    Jazz Pharmaceuticals PLC (JAZZ) does not currently pay a regular dividend.

    What is JAZZ's P/E ratio?

    Jazz Pharmaceuticals PLC has a price-to-earnings (P/E) ratio of 8.46.

    What is JAZZ's market cap?

    Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $13.61B with a current stock price of $210.39.

    Related stocks

    Sector: Healthcare

    All stocks starting with J

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In